Introduction
============

Arterial distensibility and arterial compliance decrease with age and atherosclerosis leading to increased systolic blood pressure (SBP) and a widening of the pulse pressure (PP), resulting in left ventricular hypertrophy, a risk factor for cardiovascular disease (CVD) ([@b71-vhrm-4-1361]; [@b117-vhrm-4-1361]).

Early changes in vascular properties precede the development of coronary artery disease (CAD) and hypertensive heart disease ([@b32-vhrm-4-1361]). Arterial pulse wave velocity (APWV) and compliance alterations occur early in the course of essential hypertension in relation to other CVD risk factors ([@b25-vhrm-4-1361]). Physical properties of the vasculature require a measurement of the distending force (ie, BP), using pressure transducers at relevant sites ([@b4-vhrm-4-1361]). The form of the pulse wave through the walls of the blood vessels is affected by the mechanical properties of the vessels. Pulse-wave augmentation results from reflections of the pulse wave at distal sites (such as bifurcations), such that the forward wave and reflected wave superimpose producing the typical arterial pulse wave, which differs at different sites ([@b110-vhrm-4-1361]). The PWV and the amplitude of reflected waves are increased in stiffer arteries, and are reduced with increased arterial compliance ([@b111-vhrm-4-1361]). These features are dependent on a number of hemodynamic variables, including heart rate and PP ([@b146-vhrm-4-1361]). Therefore, measurements of augmentation are generally corrected for PP and expressed as an "augmentation index" (AI^x^).

These measurements are also affected by vasoactive drugs ([@b109-vhrm-4-1361]; [@b62-vhrm-4-1361]; [@b145-vhrm-4-1361]) and by insulin ([@b142-vhrm-4-1361]) and are sensitive to inhibition of nitric oxide synthase ([@b66-vhrm-4-1361]; [@b132-vhrm-4-1361]). The application of these measurements in concert with vasodilators has been proposed as an alternative approach for the measurement of vascular function ([@b147-vhrm-4-1361]).

Arterial pulse wave velocity
============================

Measurement of arterial wave propagation as an index of vascular stiffness and vascular health dates back to the early part of the last century ([@b23-vhrm-4-1361]).

The arrival of the pulse wave at two different arterial sites is timed, and from estimates of the length of blood vessels between these sites (by measuring the distances at overlying skin sites), the velocity of this wave is calculated in m.s^−1^ ([@b110-vhrm-4-1361]; [@b76-vhrm-4-1361]; [@b144-vhrm-4-1361]). Subtleties come in correctly estimating the intervening distances. This provides a reliable measure of arterial stiffness; at a given blood pressure, the stiffer the vessel, the less time it takes for the pulse wave to travel the length of the vessel. The APWV, especially of the aorta, has emerged as an important independent predictor of cardiovascular events. APWV increases with stiffness and is defined by the Moens--Korteweg equation, PWV = √(*Eh*/2*PR*), where *E* is Young's modulus of the arterial wall, *h* is wall thickness, *R* is arterial radius at the end of diastole, and *P* is blood density ([@b76-vhrm-4-1361]).

The time delay between the arrival of a predefined part of the pulse wave, such as the foot, at two points is obtained either by simultaneous measurement, or by gating to the peak of the R-wave of the ECG. The distance travelled by the pulse wave is measured over the body surface and APWV is then calculated as distance divided by time (m.s^−1^) and depends on anatomical variation. The abdominal aorta tends to become more tortuous with age potentially leading to an underestimation of APWV ([@b141-vhrm-4-1361]). APWs can also be detected by using Doppler ultrasound ([@b133-vhrm-4-1361]) or applanation tonometry ([@b143-vhrm-4-1361]) where the pressure within a small micromanometer flattened against an artery equates to the pressure within the artery. Increases in distending pressure increase APWV ([@b23-vhrm-4-1361]). Therefore, account should be taken of the level of BP in studies that use APWV as a marker of cardiovascular risk.

An increase in HR of 40 beats per minute was shown to increase APWV by \>1 m/s ([@b70-vhrm-4-1361]). Also acute increases in heart rate (HR) markedly lower arterial distensibility, occurring in both large and middle-size muscular arteries within the range of "normal" HR values ([@b50-vhrm-4-1361]). Raised APWV occurs with a range of established cardiovascular risk factors ([@b75-vhrm-4-1361]) including age ([@b24-vhrm-4-1361]; [@b135-vhrm-4-1361]), hypercholesterolemia ([@b73-vhrm-4-1361]), type II diabetes mellitus (DM) ([@b74-vhrm-4-1361]), and sedentary lifestyle ([@b135-vhrm-4-1361]). In hypertension, carotid-femoral APWV is an independent predictor of both cardiovascular and all-cause mortality ([@b72-vhrm-4-1361]). The odds ratio for a 5 m.s^−1^ (a relatively large change in PWV) increment in PWV was 1.34 for all-cause mortality and 1.51 for cardiovascular mortality. In contrast, PP was independently related to all-cause mortality but only marginally related to cardiovascular mortality, indicating that specific assessment of arterial stiffness, with APWV, may be of greater value in the evaluation of risk. APWV ranged from 9 to 13 m.s^−1^, whereas recently quoted values of carotid-femoral PWV in healthy individuals with average ages of 24 to 62 years ranged from around 6 to 10 m.s^−1^ ([@b112-vhrm-4-1361]). In hypertensive subjects without a history of overt cardiovascular disease APWV also predicts the occurrence of cardiovascular events independently of classic risk factors ([@b22-vhrm-4-1361]). Aortic APWV \>13 m.s^−1^ is a particularly strong predictor of cardiovascular mortality in hypertension ([@b19-vhrm-4-1361]). Carotid-femoral APWV significantly increases at a faster rate in treated hypertensives than in normotensive controls, although where BP was well controlled APWV progression was attenuated ([@b13-vhrm-4-1361]).

Aortic APWV, assessed by using Doppler flow recordings, independently predicts mortality in patients with end-stage renal failure (ESRF), a population with a particularly high rate of cardiovascular disease ([@b20-vhrm-4-1361]; [@b122-vhrm-4-1361]). The benefit associated with BP control in ESRF, by the use of anti-hypertensives, was independently related to change in aortic APWV, such that a reduction in APWV of 1 m.s^−1^ was associated with a relative risk of 0.71 for all-cause mortality ([@b53-vhrm-4-1361]).

The mechanisms of arterial stiffness
====================================

Windkessel theory treats the circulation as a central elastic reservoir (the large arteries), into which the heart pumps, and from which blood travels to the tissues through relatively nonelastic conduits ([@b105-vhrm-4-1361]). The elasticity of the proximal large arteries is the result of the high elastin to collagen ratio in their walls, which progressively declines toward the periphery. The increase in arterial stiffness that occurs with age ([@b54-vhrm-4-1361]) is the result of progressive elastic fibre degeneration ([@b7-vhrm-4-1361]). The aorta and its major branches are large arteries, which can be differentiated from the more muscular conduit arteries, such as the brachial and radial arteries. The elasticity of a given arterial segment is not constant but instead depends on its distending pressure ([@b54-vhrm-4-1361]; [@b51-vhrm-4-1361]). As distending pressure increases, there is greater recruitment of relatively inelastic collagen fibres and, consequently, a reduction in elasticity ([@b9-vhrm-4-1361]). In addition to collagen and elastin, the endothelium ([@b146-vhrm-4-1361]) and arterial wall smooth muscle bulk and tone ([@b10-vhrm-4-1361]) also influence elasticity. A number of genetic influences on arterial stiffness have also been identified. Polymorphic variation in the fibrillin-1 receptor ([@b89-vhrm-4-1361]), angiotensin II type-1 receptor and endothelin receptor ([@b68-vhrm-4-1361]) genes are related to stiffness. The angiotensin-converting enzyme (ACE) I/D polymorphism has been associated with stiffness ([@b8-vhrm-4-1361]), but not consistently ([@b69-vhrm-4-1361]). As a consequence of differing elastic qualities and wave reflection, the shape of the arterial waveform varies throughout the arterial tree. In healthy, relatively young subjects, whereas mean arterial pressure (MAP) declines in the peripheral circulation, SBP and PP are amplified ([@b67-vhrm-4-1361]). This amplification is exaggerated during exercise ([@b120-vhrm-4-1361]) but reduces with increasing age ([@b145-vhrm-4-1361]). APWV in the brachial artery has been shown to increase with age, indicative of worsening arterial compliance ([@b6-vhrm-4-1361]). However, brachial artery PWV (baPWV) has been reported to change less with age than APWV in the aorta or lower limb arteries. In contrast, the assessment of distensibility using APWV is indirect and potentially affected by changes in blood flow and MAP that reflect changes in more distal resistance vessels ([@b103-vhrm-4-1361]). Atherosclerosis, hypertension, and diabetes produce macro- and micro-vascular changes that are reflected in vascular function and physical properties before the development of overt clinical disease ([@b15-vhrm-4-1361]). Endothelial cells continuously release nitric oxide (NO), which is synthesized by the endothelial isoform of NO synthase (NOS-III) ([@b96-vhrm-4-1361]; [@b46-vhrm-4-1361]). NOS-III activity is stimulated by chemical agonists such as serotonin, acetylcholine (ACh) and bradykinin ([@b48-vhrm-4-1361]; [@b31-vhrm-4-1361]; [@b101-vhrm-4-1361]) and by flow-induced shear forces on the endothelial cell wall ([@b114-vhrm-4-1361]; [@b28-vhrm-4-1361]; [@b91-vhrm-4-1361]). Endothelium-derived NO diffuses toward the underlying vascular smooth muscle, producing relaxation. The vascular endothelium, therefore, plays a central role in the modulation of arterial smooth muscle tone and thus influences large-artery distensibility and the mechanical performance of the cardiovascular system ([@b115-vhrm-4-1361]). By improving arterial elasticity, endothelium-derived NO reduces the arterial wave reflection and reduces left ventricular work and the pulse pressure within the aorta. In addition, exogenous acetylcholine and glyceryl trinitrate (GTN) both increase arterial distensibility, the former mainly through NO production. This may help explain why conditions that exhibit endothelial dysfunction are also associated with increased arterial stiffness. Therefore, reversal of endothelial dysfunction or drugs that are large-artery vasorelaxants may be effective in reducing large-artery stiffness in humans, and thus cardiovascular risk. GTN reduces brachial artery stiffness and decreases wave reflection ([@b149-vhrm-4-1361]). Moreover, drugs that stimulate endothelial NO release, such as ACh, also reduce muscular artery stiffness in vivo ([@b115-vhrm-4-1361]; [@b60-vhrm-4-1361]).

Specific studies in exercise
----------------------------

Changes in APWV in dynamic exercise in normal individuals, may provide a reference point against which to compare the effect of disease states and the basis for evaluation of their component mechanisms ([@b99-vhrm-4-1361]). Aerobic exercise training increases arterial compliance and reduces SBP and in cross-sectional studies, aerobically trained athletes have a higher arterial compliance than sedentary individuals ([@b95-vhrm-4-1361]; [@b63-vhrm-4-1361]; [@b135-vhrm-4-1361]). Hammer throwers recorded significantly higher compliance in the radial artery of the dominant arm relative to both the contra-lateral arm and to an inactive control group ([@b49-vhrm-4-1361]). This could be explained by the dynamic nature of the action.

A single bout of cycling exercise increased whole body arterial compliance by mechanisms suggesting vasodilation. In exercising muscles, factors including local increases in temperature, carbon dioxide, acidity, adenosine, NO and magnesium and potassium ions may all contribute to local vasodilation ([@b64-vhrm-4-1361]). Four weeks of cycle training, in sedentary individuals, significantly increased forearm blood flow and blood viscosity, suggesting an increased basal production of nitric oxide from the forearm. The elevated shear stress in this vascular bed may contribute to endothelial adaptation ([@b65-vhrm-4-1361]). Both the proximal aorta and the leg arteries were significantly stiffer and contributed to significantly higher aortic characteristic impedance in strength-trained athletes ([@b16-vhrm-4-1361]). However, large-artery stiffening associated with isolated systolic hypertension (ISH) is resistant to modification through short-term aerobic training ([@b44-vhrm-4-1361]). In subjects 70 to 100 years old, aortic APWV was a strong, independent significant predictor of cardiovascular death, whereas systolic blood pressure or pulse pressure was not ([@b88-vhrm-4-1361]). GTN, an exogenous NO donor significantly increased brachial artery area and compliance and significantly decreased pulse wave velocity ([@b66-vhrm-4-1361]). In contrast to the beneficial effect of regular aerobic exercise, resistance training does not exert beneficial influences on arterial wall buffering functions ([@b93-vhrm-4-1361]). However, several months of resistance training "reduced" central arterial compliance in healthy men ([@b94-vhrm-4-1361]). The 3-hydroxyl-3-methyl coenzyme A reductase inhibitors (statins), significantly reduced total and low-density lipoprotein cholesterol and triglyceride levels and increased high density lipoprotein cholesterol and significantly lowered APWV ([@b45-vhrm-4-1361]). Atorvastatin significantly reduced arterial stiffness in patients with rheumatoid arthritis, possibly through an anti-inflammatory action ([@b138-vhrm-4-1361]). Age, blood pressure, body mass index (BMI), triglycerides, blood glucose and uric acid were shown to be significant variables for baPWV in both genders ([@b134-vhrm-4-1361]). Central aortic stiffness would appear to be the initial main site for promotion of the development of coronary atherosclerosis and ischemic heart disease ([@b86-vhrm-4-1361]).

Physiology of growth hormone (GH)
=================================

The ability of the somatotroph cells in the anterior pituitary to synthesize and secrete the polypeptide, human growth hormone (hGH) are determined by a gene called the Prophet of Pit-1 (PROP1). When GH is translated, 70%--80% is secreted as a 191-amino-acid, 4-helix bundle protein and 20%--30% as a less abundant 176-amino-acid form ([@b11-vhrm-4-1361]) ([Figure 1](#f1-vhrm-4-1361){ref-type="fig"}). Hypothalamic-releasing and hypothalamic-inhibiting hormones acting via the hypophysial portal system control the secretion of GH, which is secreted into the circulation ([@b90-vhrm-4-1361]).

In healthy persons, the GH level is usually \<0.2 μg.L^−1^ throughout most of the day. There are approximately 10--12 intermittent bursts in a 24-hour period, mostly at night, when the level can rise to 30 μg.L^−1^ ([@b90-vhrm-4-1361]). GH secretion declines at 14% per decade from the age of 20 years ([@b59-vhrm-4-1361]).

GH action is mediated by a GH receptor, which is expressed mainly in the liver and is composed of dimers that change conformation when occupied by a GH ligand ([@b27-vhrm-4-1361]).

Cleavage of the GH receptor provides a circulating GH binding protein (GHBP), prolonging the half-life and mediating the transport of GH. Growth hormone activates the growth hormone receptor, to which the intracellular Janus kinase 2 (JAK2) tyrosine kinase binds. Both the receptor and JAK2 protein are phosphorylated, and signal transducers and activators of transcription (STAT) proteins bind to this complex. STAT proteins are then phosphorylated and translocated to the nucleus, which initiates transcription of growth hormone target proteins ([@b3-vhrm-4-1361]).

Intracellular GH signalling is suppressed by suppressors of cytokine signalling. GH induces the synthesis of peripheral insulin-like growth factor I (IGF-I) ([@b79-vhrm-4-1361]) and endocrine, autocrine and paracrine IGF-I induces cell proliferation and is thought to inhibit apoptosis ([@b108-vhrm-4-1361]).

IGF-binding proteins (IGFBP) and their proteases regulate the access of ligands to the IGF-I receptor affecting its action. Levels of IGF-I are at their peak during late adolescence and decline throughout adulthood, mirror imaging GH and are determined by sex and genetic factors ([@b92-vhrm-4-1361]). IGF-I levels reflect the secretory activity of growth hormone and is a marker for identification of GH-deficiency (GHD), or excess ([@b84-vhrm-4-1361]). The production of IGF-I is suppressed in malnourished patients, as well as in certain disease states, such as liver disease, hypothyroidism, or poorly controlled diabetes.

In conjunction with GH, IGF-I has varying differential effects on protein, glucose, lipid and calcium metabolism and therefore body composition ([@b85-vhrm-4-1361]). Direct effects result from the interaction of GH with its specific receptors on target cells. In the adipocyte, GH stimulates the cell to break down triglyceride and suppresses its ability to uptake and accumulate circulating lipids. Indirect effects are mediated primarily by IGF-I.

Little is known about the expression of skeletal muscle-specific isoforms of IGF-I gene in response to exercise in humans, nor the influence of age and physical training status. A single bout of isometric exercise stimulated the expression of mRNA for the IGF-I splice variants IGF-IEa and IGF-IEc (mechano growth factor \[MGF\]) within 2.5 hours, which lasts for at least 2 days after exercise ([@b52-vhrm-4-1361]).

Gh deficiency (GHD)
===================

The therapeutic indications for recombinant human growth hormone (rhGH) in the UK are controlled by the [@b102-vhrm-4-1361], which has very strict guidelines and has recommended treatment with rhGH for children with: Growth disturbance in short children born small for gestational ageProven GH deficiencyGonadal dysgenesis (Turner's syndrome)Prader--Willi syndromeChronic renal insufficiency before puberty (renal function decreased to less than 50%).

Treatment should be initiated and monitored by a pediatrician with expertise in managing GH disorders; treatment can be continued under a shared-care protocol by a general practitioner. Treatment should be discontinued if the response is poor (ie, an increase in growth velocity of less than 50% from baseline) in the first year of therapy. In children with chronic renal insufficiency, treatment should be stopped after renal transplantation and not restarted for at least a year. [@b102-vhrm-4-1361] has recommended rhGH in adults only if the following three criteria are fulfilled: Severe GH deficiency, established by an appropriate methodImpaired quality of life, measured by means of a specific questionnaireAlready receiving treatment for another pituitary hormone deficiency.

Treatment should be discontinued if the quality of life has not improved sufficiently by nine months. Severe GHD developing after linear growth is complete but before the age of 25 years should be treated with rhGH; treatment should continue until adult peak bone mass has been achieved. Treatment for adult-onset GH (A-OGH) deficiency should be stopped only when the patient and the patient's physician consider it appropriate. Treatment with somatropin should be initiated and managed by a physician with expertise in GH disorders; maintenance treatment can be prescribed in the community under a shared-care protocol ([@b26-vhrm-4-1361]). A-OGH deficient individuals are overweight, with reduced lean body mass (LBM) ([@b123-vhrm-4-1361]; [@b2-vhrm-4-1361]; [@b17-vhrm-4-1361]) and increased fat mass (FM), especially abdominal adiposity ([@b123-vhrm-4-1361]; [@b14-vhrm-4-1361]; [@b2-vhrm-4-1361]; [@b17-vhrm-4-1361]; [@b129-vhrm-4-1361]). They have reduced total body water ([@b21-vhrm-4-1361]) and reduced bone mass ([@b61-vhrm-4-1361]; [@b104-vhrm-4-1361]; [@b57-vhrm-4-1361]). There is also reduced strength and exercise capacity ([@b34-vhrm-4-1361], [@b35-vhrm-4-1361], [@b36-vhrm-4-1361]) and reduced cardiac performance and an altered substrate metabolism ([@b18-vhrm-4-1361]; [@b47-vhrm-4-1361]; [@b121-vhrm-4-1361]; [@b106-vhrm-4-1361]; [@b55-vhrm-4-1361]). This leads to an abnormal lipid profile ([@b38-vhrm-4-1361]; [@b118-vhrm-4-1361]; [@b40-vhrm-4-1361]; [@b5-vhrm-4-1361]) which can predispose to the development of cardiovascular disease. A-OGH deficiency reduces psychological well-being and quality of life (QoL) ([@b130-vhrm-4-1361]; [@b119-vhrm-4-1361]). The use of rhGH is currently being used successfully to treat this deficiency.

GH excess (acromegaly)
======================

GH excess results in the clinical condition known as acromegaly. This condition is presented as a consequence of a pituitary tumor characterized by a multitude of signs and symptoms. Pituitary tumors account for approximately 15% of primary intracranial tumors ([@b90-vhrm-4-1361]). Acromegalics have an increased risk of DM, hypertension and premature mortality due to CVD ([@b14-vhrm-4-1361]).

The most common side effects following administration arise from sodium and water retention.

Weight gain, dependent edema, a sensation of tightness in the hands and feet, or carpal tunnel syndrome; can frequently occur within days ([@b56-vhrm-4-1361]).

Arthralgia (joint pain), involving small or large joints can occur, but there is usually no evidence of effusion, inflammation, or X-ray changes ([@b123-vhrm-4-1361]). Muscle pains can also occur. GH administration is documented to result in hyperinsulinemia ([@b58-vhrm-4-1361]) which may increase the risk of cardiovascular complications. GH-induced hypertension ([@b123-vhrm-4-1361]) and atrial fibrillation ([@b14-vhrm-4-1361]) have both been reported, but are rare. There have also been reports of cerebral side effects, such as encephalocele ([@b123-vhrm-4-1361]) and headache with tinnitus ([@b14-vhrm-4-1361]) and benign intra-cranial hypertension ([@b83-vhrm-4-1361]).

Cessation of GH therapy is associated with regression of side effects in most cases ([@b83-vhrm-4-1361]).

APWV in pathological GH states
==============================

The potential mechanisms accounting for this abnormality may result from a direct IGF-I mediated effect via increased production of NO. Qualitative alterations in lipoproteins have been described in GHD adults ([@b107-vhrm-4-1361]), resulting in the generation of an atherogenic lipoprotein phenotype, which would contribute to endothelial dysfunction.

Growth hormone deficiency (GHD)
-------------------------------

Increased oxidative stress exists in GHD adults, which may be a factor in atherogenesis and reduced by GH therapy's effects on oxidative stress ([@b42-vhrm-4-1361]). Endothelial dysfunction exists in GHD adults ([@b43-vhrm-4-1361]), which is reversible with GH replacement ([@b113-vhrm-4-1361]). An impaired endothelial-dependent dilatation (EDD) response was documented in GHD adults, which significantly improved after GH treatment.

Patients with GHD, with increased risk of vascular disease, have impaired endothelial function and increased AI^x^ compared with controls. Replacement of GH resulted in improvement of both endothelial function and AI^x^, without changing BP ([@b127-vhrm-4-1361]).

Replacement of GH for 3 months corrected endothelial dysfunction in patents with chronic heart failure ([@b100-vhrm-4-1361]).

Renal failure induces GH resistance at the receptor and post-receptor level, with concomitant endothelial dysfunction, which can be overcome by replacement of GH ([@b80-vhrm-4-1361]).

Growth hormone excess
=====================

Acromegaly is associated with changes in the central arterial pressure waveform, suggesting large artery stiffening. This may have important implications for cardiac morphology and performance as well as increasing the susceptibility to atheromatous disease.

Large artery stiffness is reduced in "cured" acromegaly (GH \< 2.5 mU.L^−1^) and partially reversed after pharmacological treatment of active disease ([@b128-vhrm-4-1361]).

GH and inflammatory markers of CVD
==================================

Human peripheral blood T cells, B cells, natural killer (NK) cells, and monocytes express IGF-I receptors ([@b148-vhrm-4-1361]). Administration of either GH or IGF-I can reverse the immunodeficiency of Snell dwarf mice ([@b137-vhrm-4-1361]). GH replacement induced a significant overall increase in the percent specific lysis of K562 tumor target cells, in healthy adults ([@b33-vhrm-4-1361]). NK activity was significantly increased throughout the six weeks period of administration. In vitro studies, using human lymphocytes indicate that GH is important for the development of the immune system ([@b148-vhrm-4-1361]). However, pre-operative administration of GH did not alter C-reactive protein (CRP), serum amyloid A (SAA) or interleukin-6 (IL-6, an inflammatory cytokine) release ([@b87-vhrm-4-1361]). Homocysteine (HCY) concentration has been established as an independent risk factor for atherosclerosis ([@b41-vhrm-4-1361]; [@b131-vhrm-4-1361]). CRP and IL-6 levels and central fat decreased significantly in rhGH recipients in GHD after 18 months. Lipoprotein(a) and glucose levels significantly increased, without affecting lipid levels ([@b125-vhrm-4-1361]). HCY impairs vascular endothelial function through significant reduction of NO production. This appears to potentiate oxidative stress and atherogenic development ([@b139-vhrm-4-1361]). HCY levels were not significantly elevated in GHD adults and HCY was considered to be unlikely to be a major risk factor for vascular disease, if there are no other risk factors present ([@b1-vhrm-4-1361]). Pegvisomant (GH receptor antagonist) did not induce significant acute changes in the major risk markers for CVD, in apparently healthy abdominally obese men ([@b98-vhrm-4-1361]). This suggested that the secondary metabolic changes, eg, inflammatory factors, which develop as a result of long-standing GHD are of primary importance in the pathogenesis of atherosclerosis in patients with GHD. Patients with active acromegaly have significantly lower CRP and significantly higher insulin levels than healthy controls and administration of pegvisomant significantly increased CRP to normal levels ([@b126-vhrm-4-1361]). GH secretory status may be an important determinant of serum CRP levels, but the mechanism and significance of this finding is as yet unknown. Inflammatory markers are predictive of atherosclerosis and cardiovascular events ([@b116-vhrm-4-1361]; [@b39-vhrm-4-1361]). The metabolic syndrome (MS) is correlated with elevated CRP and a predictor of coronary heart disease and DM ([@b124-vhrm-4-1361]). IL-6 concentrations were significantly increased in GHD, compared to BMI-matched and nonobese controls, respectively ([@b78-vhrm-4-1361]). CRP significantly increased in patients compared to nonobese controls, but not significantly different compared to BMI-matched controls. Age, LDL-cholesterol, and IL-6 were positively correlated, and IGF-I was negatively correlated to arterial intima-media thickness (IMT) in the patient group, but only age and IL-6 were independently related to IMT.

Potential mechanisms
====================

Oxidative stress represents a mechanism leading to the destruction of neuronal and vascular cells.

Oxidative stress occurs as a result of the production of free radicals or reactive oxygen species (ROS). ROS consist of entities including the superoxide anion, hydrogen peroxide, superoxide anion, NO, and peroxynitrite. The production of ROS, such as peroxynitrite and NO, can lead to cell injury through cell membrane lipid destruction and cleavage of DNA ([@b140-vhrm-4-1361]). Production of excess ROS can result in the peroxidation of docosahexenoic acid (DHA), a precursor of neuroprotective docosanoids ([@b97-vhrm-4-1361]). DHA is a fatty acid released from membrane phospholipids and is derived from dietary essential fatty acids. It is involved in memory formation, excitable membrane function, photoreceptor cell biogenesis and function and neuronal signaling. DHA may have a role in modulating IGF-I binding in retinal cells ([@b150-vhrm-4-1361]). Neuroprotectin D1 (NPD1) is a DHA-derived mediator that protects the central nervous system (brain and retina) against cell injury-induced oxidative stress, in cerebral ischemia-reperfusion. It up-regulates the anti-apoptotic Bcl-2 proteins, Bcl-2, and Bclxl and decreases pro-apoptotic Bax and Bad expression ([@b12-vhrm-4-1361]).

IGF-I also blocks Bcl-2 interacting mediator of cell death (Bim) induction and intrinsic death signalling in cerebellar granule neurons ([@b81-vhrm-4-1361]).

Dorsal root ganglia (DRG) neurons express IGF-I receptors (IGF-IR), and IGF-I activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. High glucose exposure induces apoptosis, which is inhibited by IGF-I through the PI3K/Akt pathway. IGF-I stimulation of the PI3K/Akt pathway phosphorylates three known Akt effectors: the survival transcription factor cyclic AMP response element binding protein (CREB) and the pro-apoptotic effector proteins glycogen synthase kinase-3beta (GSK-3beta) and forkhead (FKHR). IGF-I regulates survival at the nuclear level through accumulation of phospho-Akt in DRG neuronal nuclei, increased CREB-mediated transcription, and nuclear exclusion of FKHR. High glucose levels increase expression of the pro-apoptotic Bcl protein Bim (a transcriptional target of FKHR). High glucose also induces loss of the initiator caspase-9 and increases caspase-3 cleavage, effects blocked by IGF-I, suggesting that IGF-I prevents apoptosis in DRG neurons by regulating PI3K/Akt pathway effectors, including GSK-3beta, CREB, and FKHR, and by blocking caspase activation ([@b77-vhrm-4-1361]).

The unique role of IGF-IR in maintaining the balance of death and survival in foetal brown adipocytes, in IGF-IR deficiency has been demonstrated ([@b136-vhrm-4-1361]).

A vascular protective role for IGF-I has been suggested because of its ability to stimulate NO production from endothelial and vascular smooth muscle cells. IGF-I probably plays a role in aging, atherosclerosis and cerebrovascular disease, cognitive decline, and dementia. In cross sectional studies, low IGF-I levels have been associated with an unfavorable profile of CVD risk factors, such as atherosclerosis, abnormal lipoprotein levels and hypertension, while in prospective studies, lower IGF-I levels predict future development of ischemic heart disease. The fall in the levels of GH ([@b59-vhrm-4-1361]) and IGF-I ([@b92-vhrm-4-1361]) with aging correlates with cognitive decline and it has been suggested that IGF-I plays a role in the development of dementia. IGF-I is highly expressed within the brain and is essential for normal brain development. IGF-I has anti-apoptotic and neuroprotective effects and promotes projection neuron growth, dendritic arborization and synaptogenesis ([@b30-vhrm-4-1361]).

Conclusion
==========

Collectively, these data are consistent with a causal link between the age-related decline in GH and IGF-I levels and cardiovascular and cerebrovascular disease in senescence. Research into the benefits of replacement hormone therapy is still in its infancy. It was only three decades ago that rhGH became available and significant progress into the somatopause and related pathologies has occurred. Could the future propose the concomitant use of rhGH and rhIGF as has been used in certain refractory cases of diabetes and GH resistance ([@b84-vhrm-4-1361])? The reviews of rhGH replacement in obesity have not been revolutionary ([@b82-vhrm-4-1361]). It might be expedient to research the combination of rhGH and rhIGF in the variety of physiological GHD states to determine any beneficial effects. After all, it wasn't until 1999 that hypothyroidism was identified as being more appropriately treated with tri-iodothyronine (T~3~) and tetra-iodothyronine (T~4~), than T~4~ alone ([@b29-vhrm-4-1361]).
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